TrialClinical pharmacology in drug development2020

Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.

Meera Tugnait et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.